Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
Identifieur interne : 000029 ( PubMed/Checkpoint ); précédent : 000028; suivant : 000030Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
Auteurs : A L Marano [États-Unis] ; J M Clarke [États-Unis] ; M A Morse [États-Unis] ; A. Shah [États-Unis] ; W. Barrow [États-Unis] ; M A Selim [États-Unis] ; R P Hall [États-Unis] ; A R Cardones [États-Unis]Source :
- The British journal of dermatology [ 1365-2133 ] ; 2019.
Abstract
Programmed cell death 1 (PD-1) blockade has rapidly emerged as an effective therapy for a wide variety of metastatic malignancies. It has been associated with multiple immune-related adverse effects, including cutaneous eruptions. We describe two patients with clinical and histological findings that were consistent with subacute cutaneous lupus erythematosus (SCLE) after receiving PD-1 inhibitor therapy for metastatic lung cancer. We successfully treated our first patient with systemic and topical steroids, photoprotection and hydroxychloroquine. However, he subsequently developed dermatomyositis after continuing PD-1 inhibitor therapy. Our second patient presented with a protracted course of a cutaneous eruption in spite of discontinuation of anti-PD-1 therapy and treatment with systemic corticosteroids and infliximab. This patient's SCLE resolved after the addition of topical steroids and photoprotection and discontinuation of anti-tumour necrosis factor therapy. She and her oncology team decided to pursue non-PD-1 inhibitor treatment for lung cancer owing to a lack of tumour response. We add SCLE and dermatomyositis to the growing list of autoimmune complications of PD-1 blockade. Our cases raise a number of questions, particularly in relation to the viability of continuing anti-PD-1 therapy after developing SCLE and the role of immunosuppressive therapy in patients with PD-1 inhibitor-associated connective tissue disease. What's already known about this topic? Programmed cell death 1 (PD-1) blockade, which is rapidly emerging as a therapy for a wide variety of metastatic malignancies, has been associated with multiple immune-related adverse effects. These include systemic autoimmune diseases such as colitis and thyroiditis in addition to numerous cutaneous adverse events. Cutaneous side-effects of PD-1 inhibitors most commonly reported in clinical trials include lichenoid reactions, eczematous dermatitis and vitiligo. What does this study add? We report two cases of PD-1 inhibitor-associated subacute cutaneous lupus erythematosus (SCLE), with one patient progressing to dermatomyositis with continued PD-1 inhibitor treatment. In addition to being a novel cutaneous adverse event, we also demonstrate the possibility of development of multiple autoimmune diseases in one patient, which is different from classic drug-related SCLE. We discuss the treatment challenges for patients with autoimmune skin disease receiving PD-1 inhibitor therapy.
DOI: 10.1111/bjd.17245
PubMed: 30244487
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:30244487Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.</title><author><name sortKey="Marano, A L" sort="Marano, A L" uniqKey="Marano A" first="A L" last="Marano">A L Marano</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Clarke, J M" sort="Clarke, J M" uniqKey="Clarke J" first="J M" last="Clarke">J M Clarke</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Morse, M A" sort="Morse, M A" uniqKey="Morse M" first="M A" last="Morse">M A Morse</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Shah, A" sort="Shah, A" uniqKey="Shah A" first="A" last="Shah">A. Shah</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Barrow, W" sort="Barrow, W" uniqKey="Barrow W" first="W" last="Barrow">W. Barrow</name><affiliation wicri:level="2"><nlm:affiliation>Ameripath Inc., Palm Beach Gardens, FL, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Ameripath Inc., Palm Beach Gardens, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Selim, M A" sort="Selim, M A" uniqKey="Selim M" first="M A" last="Selim">M A Selim</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Hall, R P" sort="Hall, R P" uniqKey="Hall R" first="R P" last="Hall">R P Hall</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Cardones, A R" sort="Cardones, A R" uniqKey="Cardones A" first="A R" last="Cardones">A R Cardones</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30244487</idno><idno type="pmid">30244487</idno><idno type="doi">10.1111/bjd.17245</idno><idno type="wicri:Area/PubMed/Corpus">000082</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000082</idno><idno type="wicri:Area/PubMed/Curation">000082</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000082</idno><idno type="wicri:Area/PubMed/Checkpoint">000029</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000029</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.</title><author><name sortKey="Marano, A L" sort="Marano, A L" uniqKey="Marano A" first="A L" last="Marano">A L Marano</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Clarke, J M" sort="Clarke, J M" uniqKey="Clarke J" first="J M" last="Clarke">J M Clarke</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Morse, M A" sort="Morse, M A" uniqKey="Morse M" first="M A" last="Morse">M A Morse</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Shah, A" sort="Shah, A" uniqKey="Shah A" first="A" last="Shah">A. Shah</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Barrow, W" sort="Barrow, W" uniqKey="Barrow W" first="W" last="Barrow">W. Barrow</name><affiliation wicri:level="2"><nlm:affiliation>Ameripath Inc., Palm Beach Gardens, FL, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Ameripath Inc., Palm Beach Gardens, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Selim, M A" sort="Selim, M A" uniqKey="Selim M" first="M A" last="Selim">M A Selim</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Hall, R P" sort="Hall, R P" uniqKey="Hall R" first="R P" last="Hall">R P Hall</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Cardones, A R" sort="Cardones, A R" uniqKey="Cardones A" first="A R" last="Cardones">A R Cardones</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author></analytic><series><title level="j">The British journal of dermatology</title><idno type="eISSN">1365-2133</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Programmed cell death 1 (PD-1) blockade has rapidly emerged as an effective therapy for a wide variety of metastatic malignancies. It has been associated with multiple immune-related adverse effects, including cutaneous eruptions. We describe two patients with clinical and histological findings that were consistent with subacute cutaneous lupus erythematosus (SCLE) after receiving PD-1 inhibitor therapy for metastatic lung cancer. We successfully treated our first patient with systemic and topical steroids, photoprotection and hydroxychloroquine. However, he subsequently developed dermatomyositis after continuing PD-1 inhibitor therapy. Our second patient presented with a protracted course of a cutaneous eruption in spite of discontinuation of anti-PD-1 therapy and treatment with systemic corticosteroids and infliximab. This patient's SCLE resolved after the addition of topical steroids and photoprotection and discontinuation of anti-tumour necrosis factor therapy. She and her oncology team decided to pursue non-PD-1 inhibitor treatment for lung cancer owing to a lack of tumour response. We add SCLE and dermatomyositis to the growing list of autoimmune complications of PD-1 blockade. Our cases raise a number of questions, particularly in relation to the viability of continuing anti-PD-1 therapy after developing SCLE and the role of immunosuppressive therapy in patients with PD-1 inhibitor-associated connective tissue disease. What's already known about this topic? Programmed cell death 1 (PD-1) blockade, which is rapidly emerging as a therapy for a wide variety of metastatic malignancies, has been associated with multiple immune-related adverse effects. These include systemic autoimmune diseases such as colitis and thyroiditis in addition to numerous cutaneous adverse events. Cutaneous side-effects of PD-1 inhibitors most commonly reported in clinical trials include lichenoid reactions, eczematous dermatitis and vitiligo. What does this study add? We report two cases of PD-1 inhibitor-associated subacute cutaneous lupus erythematosus (SCLE), with one patient progressing to dermatomyositis with continued PD-1 inhibitor treatment. In addition to being a novel cutaneous adverse event, we also demonstrate the possibility of development of multiple autoimmune diseases in one patient, which is different from classic drug-related SCLE. We discuss the treatment challenges for patients with autoimmune skin disease receiving PD-1 inhibitor therapy.</div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">30244487</PMID><DateRevised><Year>2020</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2133</ISSN><JournalIssue CitedMedium="Internet"><Volume>181</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The British journal of dermatology</Title><ISOAbbreviation>Br. J. Dermatol.</ISOAbbreviation></Journal><ArticleTitle>Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.</ArticleTitle><Pagination><MedlinePgn>580-583</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bjd.17245</ELocationID><Abstract><AbstractText>Programmed cell death 1 (PD-1) blockade has rapidly emerged as an effective therapy for a wide variety of metastatic malignancies. It has been associated with multiple immune-related adverse effects, including cutaneous eruptions. We describe two patients with clinical and histological findings that were consistent with subacute cutaneous lupus erythematosus (SCLE) after receiving PD-1 inhibitor therapy for metastatic lung cancer. We successfully treated our first patient with systemic and topical steroids, photoprotection and hydroxychloroquine. However, he subsequently developed dermatomyositis after continuing PD-1 inhibitor therapy. Our second patient presented with a protracted course of a cutaneous eruption in spite of discontinuation of anti-PD-1 therapy and treatment with systemic corticosteroids and infliximab. This patient's SCLE resolved after the addition of topical steroids and photoprotection and discontinuation of anti-tumour necrosis factor therapy. She and her oncology team decided to pursue non-PD-1 inhibitor treatment for lung cancer owing to a lack of tumour response. We add SCLE and dermatomyositis to the growing list of autoimmune complications of PD-1 blockade. Our cases raise a number of questions, particularly in relation to the viability of continuing anti-PD-1 therapy after developing SCLE and the role of immunosuppressive therapy in patients with PD-1 inhibitor-associated connective tissue disease. What's already known about this topic? Programmed cell death 1 (PD-1) blockade, which is rapidly emerging as a therapy for a wide variety of metastatic malignancies, has been associated with multiple immune-related adverse effects. These include systemic autoimmune diseases such as colitis and thyroiditis in addition to numerous cutaneous adverse events. Cutaneous side-effects of PD-1 inhibitors most commonly reported in clinical trials include lichenoid reactions, eczematous dermatitis and vitiligo. What does this study add? We report two cases of PD-1 inhibitor-associated subacute cutaneous lupus erythematosus (SCLE), with one patient progressing to dermatomyositis with continued PD-1 inhibitor treatment. In addition to being a novel cutaneous adverse event, we also demonstrate the possibility of development of multiple autoimmune diseases in one patient, which is different from classic drug-related SCLE. We discuss the treatment challenges for patients with autoimmune skin disease receiving PD-1 inhibitor therapy.</AbstractText><CopyrightInformation>© 2018 British Association of Dermatologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marano</LastName><ForeName>A L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke Cancer Institute, Duke University Medical Center, Durham, NC, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morse</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke Cancer Institute, Duke University Medical Center, Durham, NC, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology, Duke University Medical Center, Durham, NC, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrow</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Ameripath Inc., Palm Beach Gardens, FL, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selim</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Duke University Medical Center, Durham, NC, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>R P</ForeName><Initials>RP</Initials><Suffix>3rd</Suffix><Identifier Source="ORCID">http://orcid.org/0000-0001-7621-4935</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Duke University Medical Center, Durham, NC, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardones</LastName><ForeName>A R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-7489-2046</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke Cancer Institute, Duke University Medical Center, Durham, NC, U.S.A.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Dermatol</MedlineTA><NlmUniqueID>0004041</NlmUniqueID><ISSNLinking>0007-0963</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>09</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30244487</ArticleId><ArticleId IdType="doi">10.1111/bjd.17245</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Nishimura H, Nose M, Hiai H et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11:141-51.</Citation></Reference><Reference><Citation>Hwang SJ, Carlos G, Wakade D et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 2016; 74(455-61):e1.</Citation></Reference><Reference><Citation>Marzano AV, Lazzari R, Polloni I et al. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol 2011; 165:335-41.</Citation></Reference><Reference><Citation>Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus 2009; 18:935-40.</Citation></Reference><Reference><Citation>Fiorentino D, Chung L, Zwerner J et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65:25-34.</Citation></Reference><Reference><Citation>Gotot J, Gottschalk C, Leopold S et al. Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. Proc Natl Acad Sci USA 2012; 109:10468-73.</Citation></Reference><Reference><Citation>Prokunina L, Castillejo-Lopez C, Oberg F et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002; 32:666-9.</Citation></Reference><Reference><Citation>Wang SC, Chen YJ, Ou TT et al. Programmed death-1 gene polymorphisms in patients with systemic lupus erythematosus in Taiwan. J Clin Immunol 2006; 26:506-11.</Citation></Reference><Reference><Citation>Chua KH, Lian LH, Sim XJ et al. Association between PDCD1 gene polymorphisms and risk of systemic lupus erythematosus in three main ethnic groups of the malaysian population. Int J Mol Sci 2015; 16:9794-803.</Citation></Reference><Reference><Citation>Sanlorenzo M, Vujic I, Daud A et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015; 151:1206-12.</Citation></Reference><Reference><Citation>Teulings HE, Limpens J, Jansen SN et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 2015; 33:773-81.</Citation></Reference><Reference><Citation>Chen JH, Pezhouh MK, Lauwers GY, Masia R. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol 2017; 41:643-54.</Citation></Reference><Reference><Citation>Vaz JL, Fernandes V, Nogueira F et al. Infliximab-induced autoantibodies: a multicenter study. Clin Rheumatol 2016; 35:325-32.</Citation></Reference><Reference><Citation>Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2016; 2:1346-53.</Citation></Reference><Reference><Citation>Patel S, Hurez V, Nawrocki ST et al. Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. Oncotarget 2016; 7:59087-97.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Caroline du Nord</li><li>Floride</li></region></list><tree><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Marano, A L" sort="Marano, A L" uniqKey="Marano A" first="A L" last="Marano">A L Marano</name></region><name sortKey="Barrow, W" sort="Barrow, W" uniqKey="Barrow W" first="W" last="Barrow">W. Barrow</name><name sortKey="Cardones, A R" sort="Cardones, A R" uniqKey="Cardones A" first="A R" last="Cardones">A R Cardones</name><name sortKey="Clarke, J M" sort="Clarke, J M" uniqKey="Clarke J" first="J M" last="Clarke">J M Clarke</name><name sortKey="Hall, R P" sort="Hall, R P" uniqKey="Hall R" first="R P" last="Hall">R P Hall</name><name sortKey="Morse, M A" sort="Morse, M A" uniqKey="Morse M" first="M A" last="Morse">M A Morse</name><name sortKey="Selim, M A" sort="Selim, M A" uniqKey="Selim M" first="M A" last="Selim">M A Selim</name><name sortKey="Shah, A" sort="Shah, A" uniqKey="Shah A" first="A" last="Shah">A. Shah</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000029 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000029 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:30244487
|texte= Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:30244487" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |